EGFR and neoplasm: Local SBRT to the primary tumor in the early phase, at approximately the first month in our study, seemed to have good local control, with the possibility of eliminating tumor heterogeneity and thereby delaying targeted resistance in advanced EGFR-mutation-positive NSCLC treated with EGFR-TKI.